Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 8/20 | 0.40 |
| ▸ | ELANE | P08246 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319590 | 1.00 | PTGER3 (0.40) | PTGER3ELANEKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2314803 | 0.91 | ELANE (0.42) | PTGER3ELANECTRC | |
| SCHEMBL2314796 | 0.91 | ELANE (0.42) | PTGER3ELANECTRC | |
| SCHEMBL2317925 | 0.90 | ELANE (0.42) | PTGER3ELANEKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2319834 | 0.88 | ELANE (0.41) | PTGER3ELANECTRC | |
| SCHEMBL2319823 | 0.88 | ELANE (0.41) | PTGER3ELANECTRC | |
| SCHEMBL2316802 | 0.87 | PTGER3 (0.39) | PTGER3ELANECTRC | |
| SCHEMBL2316796 | 0.87 | PTGER3 (0.39) | PTGER3ELANECTRC | |
| SCHEMBL2319327 | 0.86 | ELANE (0.43) | ELANEKDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2319322 | 0.86 | ELANE (0.43) | ELANEKDM4EALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| CN-101193908-A | Organic compounds | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | PTGER3 4550/4885ELANE 2303/4885KDM4E 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.